Recruiting Multiple Myeloma Studies in Ann Arbor
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to impro...
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....
A Study of Daratumumab
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research a...
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs ...
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the contr...
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and prelimina...
Ribociclib (LEE011) Rollover Study for Continued Access
This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-spons...
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...
About Multiple Myeloma Clinical Trials in Ann Arbor
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 9 multiple myeloma clinical trials recruiting participants in Ann Arbor, MICHIGAN. These studies are seeking a combined 22,381 participants. Research is being sponsored by UMC Utrecht, Janssen Research & Development, LLC, Merck Sharp & Dohme LLC and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Ann Arbor — FAQ
Are there multiple myeloma clinical trials in Ann Arbor?
Yes, there are 9 multiple myeloma clinical trials currently recruiting in Ann Arbor, MICHIGAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Ann Arbor?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.
Are clinical trials in Ann Arbor free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 9 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov